Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Key Points

• MAIN FINDING: Acquired resistance to KRAS G12C–EGFR inhibition was identified in colorectal cancer models.
• KEY EVIDENCE: The study utilized patient-derived xenograft (PDX) models to explore resistance mechanisms.
• APPROACH: The research generated specific PDX models to mimic acquired resistance in colorectal cancer.
• SIGNIFICANCE: Understanding these mechanisms may guide future therapeutic strategies in targeting KRAS and EGFR.